Editas Medicine (EDIT) Operating Leases (2019 - 2025)

Editas Medicine (EDIT) has 7 years of Operating Leases data on file, last reported at $12.1 million in Q4 2025.

• Quarterly Operating Leases fell 40.77% year-over-year to $12.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.1 million (down 40.77% YoY) and the FY2025 annual result came in at $12.1 million, down 40.77% from the prior year.
• Operating Leases eased to $12.1 million in Q4 2025 per EDIT's latest filing, from $13.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $32.9 million in Q4 2022 and bottomed at $9.3 million in Q3 2022.
• The 5-year median for Operating Leases is $20.4 million (2024), against an average of $19.5 million.
• The widest annual swing landed in 2022, when Operating Leases sank 52.5%; it then soared 167.13% in 2023.
• Tracing EDIT's Operating Leases over 5 years: stood at $16.1 million in 2021, then jumped by 104.52% to $32.9 million in 2022, then slipped by 25.84% to $24.4 million in 2023, then retreated by 16.38% to $20.4 million in 2024, then plunged by 40.77% to $12.1 million in 2025.
• Per Business Quant, the three latest EDIT Operating Leases figures stand at $12.1 million (Q4 2025), $13.6 million (Q3 2025), and $15.0 million (Q2 2025).

Peer Comparison